Detecting disease from blood suffers from either a lack of specificity (elevated PSA means you “may” have prostate cancer), or a lack of sensitivity in early stages of disease. New DNA-based liquid biopsies, while accurate, mostly detect cancers after stage 3 when cure rates plummet.
Hummingbird Diagnostics, has over 7000 clinical samples tested and 13 granted patents in microRNA diagnostics. Their carefully engineered methodology has demonstrated sensitivity and specificity of over 90% in early stage cancers and neurodegenerative disorders.
While already receiving revenues from grants and pharmaceutical trials, the GreyBird investment will fund large clinical trials in the USA and Europe for early stage lung cancer detection. If the initial results are replicated in the larger trial, it could mean millions of lives saved through early diagnosis.